You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

From Adjuvant to Metastatic in Melanoma: What Should You Know?

  • Authors: Jeffrey S. Weber, MD, PhD; Richard D. Carvajal, MD; Douglas B. Johnson, MD
  • CME / ABIM MOC / CE Released: 12/24/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/24/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data on the use of cancer immunotherapies in the management of melanoma
  • Have greater competence related to
    • Selecting the most appropriate regimen for patients with melanoma
    • Collaborating with other members of the interprofessional team to produce optimal outcomes in the identification and management of immune-related adverse events


Moderator

  • Jeffrey S. Weber, MD, PhD

    Professor of Medicine
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, NY

    Disclosures

    Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Altor BioScience; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Celldex Therapeutics; CytomX Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
    Owns stock, stock options, or bonds from: Altor BioScience; Biond Biologics Ltd; CytomX Therapeutics, Inc.
    Other: Named on a patent for a PD-1 biomarker by Biodesix, Inc.

    Dr Weber does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Weber does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Richard D. Carvajal, MD

    Associate Professor of Medicine
    Columbia University Medical Center
    Director
    Experimental Therapeutics
    Director
    Melanoma Service
    New York, NY

    Disclosures

    Disclosure: Richard D. Carvajal, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Aura Biosciences, Inc.; Bristol-Myers Squibb Company; Castle Biosciences, Inc.; Chimeron Bio; Foundation Medicine, Inc.; Genentech, Inc.; Immunocore; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Rgenix; Roche

    Dr Carvajal does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Carvajal does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Douglas B. Johnson, MD

    Assistant Professor of Medicine
    Vanderbilt University Medical Center
    Director
    Melanoma Program
    Nashville, Tennessee

    Disclosures

    Disclosure: Douglas B. Johnson, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Array BioPharma; Bristol-Myers Squibb Company; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
    Received grants for clinical research from: Bristol-Myers Squibb Company; Incyte Corporation

    Dr Johnson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Johnson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

Members

  • Robert L. Ferris, MD, PhD

    Professor and Chief
    Division of Head and Neck Surgery
    Departments of Otolaryngology, Radiation Oncology, and Immunology
    Co-Leader
    Cancer Immunology Program
    University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania

    Disclosures

    Disclosure: Robert L. Ferris, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Benitec Bipharma Ltd; Bristol-Myers Squibb Company; EMD Serono, Inc.; Lilly; Merck & Co., Inc.; Pfizer Inc.; PPD; TESARO, Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; MedImmune Inc.; Merck & Co., Inc.; TESARO, Inc.; VentiRx

  • Ramaswamy Govindan, MD

    Professor of Medicine
    Division of Medical Oncology
    Washington University School of Medicine
    Co-Director
    Section of Medical Oncology
    Siteman Cancer Center
    Barnes-Jewish Hospital
    St Louis, Missouri

    Disclosures

    Disclosure: Ramaswamy Govindan, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adaptimmune; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; NeoHealth

  • Dung Le, MD

    Associate Professor
    Johns Hopkins University School of Medicine
    Baltimore, Maryland
    Participation by Dr Le does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System

    Disclosures

    Disclosure: Dung Le, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck & Co., Inc.
    Served as a speaker or a member of a speakers bureau for: Merck & Co., Inc.
    Received grants for clinical research from: Aduro Biotech; Bristol-Myers Squibb Company; Merck & Co., Inc.

  • Brian I. Rini, MD

    Professor of Medicine
    Lerner College of Medicine
    Director
    GU Program
    Cleveland Clinic
    Cleveland, Ohio

    Disclosures

    Disclosure: Brian I. Rini, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Merck & Co., Inc.; Pfizer Inc.
    Received grants for clinical research from: Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc.

  • Jared Weiss, MD

    Assistant Professor of Medicine
    Lineberger Comprehensive Cancer Center
    University of North Carolina at Chapel Hill

    Disclosures

    Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Celgene Corporation; EMD Serono, Inc.; G1 Therapeutics; Immunicum; Nanobiotx; Regeneron Pharmaceuticals, Inc.
    Received grants for clinical research from: Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.

Editor

  • Charlotte Warren

    Senior Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Clinical CME Director, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Additional Planners

  • Kathleen M. Madden, NP

    Nurse Practitioner
    Laura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, New York

    Disclosures

    Disclosure: Kathleen M. Madden, NP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant to: Merck & Co., Inc.

SITC Course Director

  • Paul Antony, MD

    Assistant Professor
    University of Maryland School of Medicine
    Baltimore, Maryland

    Disclosures

    Disclosure: Paul Antony, MD, has disclosed no relevant financial relationships.

SITC

  • Claire Leischer, MS

    Senior Manager of Online Education
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Claire Leischer, MS, has disclosed no relevant financial relationships.

  • Alicia Schuessler, CAE

    Director of Education
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Alicia Schuessler, CAE, has disclosed no relevant financial relationships.

  • Tara Withington, CAE

    Executive Director
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Tara Withington has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements




In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the Society for Immunotherapy of Cancer. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) ( 0.050 CEUs) (Universal Activity Number: JA0007105-0000-18-303-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

From Adjuvant to Metastatic in Melanoma: What Should You Know?

Authors: Jeffrey S. Weber, MD, PhD; Richard D. Carvajal, MD; Douglas B. Johnson, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 12/24/2018

Valid for credit through: 12/24/2019

processing....

Educational Impact Challenge

The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print